sábado, 20 de febrero de 2021

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial - The Lancet Neurology

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial - The Lancet Neurology

No hay comentarios:

Publicar un comentario